i-THYMUS
Financiado
The i-Thymus: wielding the potential of gene therapy, cell therapy and induced p...
The i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune system
Each year, >250 babies are born without a thymus. These babies have a life expectancy of 2-3 years. The only cure is transplantation of thymus tissue, but this has a 30% mortality rate and costs almost >€2.5M. We developed i-Thymu...
Each year, >250 babies are born without a thymus. These babies have a life expectancy of 2-3 years. The only cure is transplantation of thymus tissue, but this has a 30% mortality rate and costs almost >€2.5M. We developed i-Thymus, a revolutionary cure based on the patient’s own cells leveraging innovative gene therapy to generate thymus organoids that can be implanted minimally invasively in the patient (Fig. 1). We have already shown this works in functional proof of concept in vivo. With this EIC Accelerator, we will finalise development to enter the clinic for a Phase I/II trial, to enter the EU market with a pharma partner by 2028. After rapid market entry with ODD for complete DiGeorge syndrome, we will leverage this clinical success and our first revenues to develop i-Thymus for unmet needs of hundreds of thousands of other patients, starting with AML patients who have lost thymus function after high-dose chemotherapy for stem cell transplantation.
ver más
Duración del proyecto: 23 meses
Fecha Inicio: 2023-11-17
Fecha Fin: 2025-10-31
Fecha Fin: 2025-10-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-17
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2023-ACCELERATOROPEN-01:
EIC Accelerator Open 2023
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
GENEWITY BV
No se ha especificado una descripción o un objeto social para esta compañía.
